Royce & Associates LP Has $11.05 Million Stake in Indivior PLC $INDV

Royce & Associates LP increased its stake in shares of Indivior PLC (NASDAQ:INDV) by 24.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 307,857 shares of the company’s stock after purchasing an additional 61,333 shares during the period. Royce & Associates LP’s holdings in Indivior were worth $11,046,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in shares of Indivior by 3.4% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock valued at $761,000 after acquiring an additional 700 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Indivior by 17.8% in the 4th quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock worth $176,000 after acquiring an additional 733 shares during the period. Harbor Capital Advisors Inc. lifted its position in shares of Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after acquiring an additional 781 shares during the period. Salomon & Ludwin LLC bought a new stake in shares of Indivior in the 4th quarter worth approximately $30,000. Finally, GAMMA Investing LLC lifted its position in shares of Indivior by 544.6% in the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after acquiring an additional 1,013 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on INDV shares. Weiss Ratings downgraded Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $39.33.

Insiders Place Their Bets

In other Indivior news, Director Stuart A. Kingsley purchased 940 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was purchased at an average cost of $31.86 per share, with a total value of $29,948.40. Following the acquisition, the director directly owned 5,582 shares of the company’s stock, valued at approximately $177,842.52. This trade represents a 20.25% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.74% of the stock is owned by corporate insiders.

Indivior Price Performance

INDV stock opened at $37.11 on Thursday. The business has a fifty day moving average price of $33.78 and a 200 day moving average price of $33.86. Indivior PLC has a fifty-two week low of $11.83 and a fifty-two week high of $41.00. The stock has a market capitalization of $4.52 billion, a price-to-earnings ratio of 19.03 and a beta of 0.90.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The firm had revenue of $317.00 million during the quarter. On average, equities analysts expect that Indivior PLC will post 3.35 earnings per share for the current fiscal year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.